Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06177197
Other study ID # 29BRC23.0193
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date February 1, 2027

Study information

Verified date December 2023
Source University Hospital, Brest
Contact Pierrick CROS, MD
Phone 02 98 22 36 59
Email pierrick.cros@chu-brest.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to show that the use of electrodialyzed seawater reduces the duration (in days) of symptoms in acute infant bronchiolitis compared with the use of saline solution in infants aged 1 month to less than one year. B-CLASS study is a multicenter, prospective, controlled, randomized, double label blind.


Description:

This is a multicenter, prospective, controlled, randomized in 2 parrallel arms, double blind study. The Infants will be included after written informed consent will be obtained from the patients' parents or legally authorized representatives. Patients will be randomized either in the experimental group (electrodialyzed seawater) or in the control group (saline solution). Patients' parents will be call by phone at day 1, day 3, day 6, day 10 and day 21 after baseline.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 458
Est. completion date February 1, 2027
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 1 Month to 1 Year
Eligibility Inclusion Criteria: - Infants aged more than 1 month and less than 1 year - First episode of acute bronchiolitis - Emergency consultation - Existence of nasal obstruction - Onset of symptoms < 48 hours before emergency consultation - Outpatient care after emergency consultation - Mild to moderate bronchiolitis according to the "Haute Autorité de Santé 2019" criteria: Respiratory rate over 1 minute >30/minutes and <60/minute ; Heart rate >80/minutes and <180/minutes; Absence of respiratory pauses; Absence of superficial breathing; Absence of signs of intense respiratory struggle: involvement of the lower intercostal accessory muscles, sternocleidomastoid muscles, thoracoabdominal swinging, or flapping of the wings of the nose; Feeding >50% of the usual quantity over 3 consecutive doses; SpO2 > 92% during sleep ; >94% when awake; >2 months corrected age - Parental consent - Affiliate to a social security system Exclusion Criteria: - Hospitalization (excluding short stay unit) after emergency consultation - Oxygen therapy - History of prematurity (birth <34 weeks of amenorrhea) - History of invasive ventilation in the neonatal period - History of chronic pulmonary or cardiac pathology - History of immunodeficiency - History of multiple disabilities or neuromuscular pathology - History of Ear Nose and Throat pathology affecting the upper airways - Impossibility of ensuring the follow-up made necessary by participation in this study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Physiomer
Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort: Infant < 6 months: half a dose to a single dose administered per nostril 8 times a day. Infant > 6 months: one single dose administered per nostril 6 times a day.
Saline solution
Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort: Infant < 6 months: half a dose to a single dose administered per nostril 8 times a day. Infant > 6 months: one single dose administered per nostril 6 times a day.

Locations

Country Name City State
France Brest, University Hospital Brest
France Le Mans hospital Le Mans
France Lille, University hospital Lille
France Saint-Joseph hospital Marseille
France Morlaix hospital Morlaix
France Nantes, University Hospital Nantes
France Rennes, University hospital Rennes
France Tours, University hospital Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of resolution of illness (ROI) It is the time it takes for the child to return to baseline according to the person administering the care.
ROI is defined by ordinal scale from 0 to 4 on which parents globally rate symptoms according to the following categories: (1) worsened, (2) same, (3) improved, (4) resolved. The duration of ROI is the time it takes to obtain a score of 4.
At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary An again medical consultation Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Have you seen a doctor today for bronchiolitis?" YES/NO At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Hospitalization Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Is your child in hospital?" YES/NO. If yes, the length of hospital stay in hours will be collected. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Time to improvement of cough in days Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "How is the cough today?", with four possible answers (1) worsened, (2) same, (3) improved, (4) resolved. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Time to improvement of nasal congestion in days Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "How are colds today??", with four possible answers (1) worsened, (2) same, (3) improved, (4) resolved. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Length with nasopharyngeal decongestion in days Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "How many nasopharyngeal decongestion did you make today?". The duration of nasopharyngeal decongestion is the time it takes to obtain a score of 0. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Number of nasopharyngeal decongestion by day Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "How many nasopharyngeal decongestion did you make today?". At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Length of dietary resumption greater than 2/3 of usual intake. Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "How does your child eat today?". Two responses are possible : More than two-thirds, less than two-thirds.
The duration of dietary resumption greater than 2/3 of usual intake is the number of days until the response is "More than half".
At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Antibiotic use Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Is your child taking antibiotics?". YES/NO At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Length of community eviction en days Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Did your child have to be looked after today?". YES/NO. The duration of community eviction is the time to the child doesn't need to be looked after anymore. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Length of parental absence from work (in days) Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Did you have to miss work today?". YES/NO. The duration of parental absence is the number of day until that parent returns to work. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Occurrence of secondary events: epistaxis, vomiting, malaise, apnea Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Have you noticed any side effects from nasopharyngeal decongestion?". YES/NO. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Time to improvement in respiratory discomfort in days Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "Is your child suffering from respiratory problems today?", with four possible answers (1) worsened, (2) same, (3) improved, (4) resolved. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
Secondary Time to improvement in sleep quality in days Parents will be given a notebook to fill in on a daily basis. For this outcome, the following question will be asked: "How do you rate the quality of your child's sleep?", with four possible answers (1) worsened, (2) same, (3) improved, (4) resolved. At day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10
See also
  Status Clinical Trial Phase
Recruiting NCT04989114 - Nasal Bubble Continuous Positive Airway Pressure in Reducing Respiratory Distress in Children With Bronchiolitis N/A
Completed NCT04060979 - Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis Phase 2
Completed NCT03280732 - Use of Lung Ultrasound in Children With Acute Bronchiolitis N/A
Recruiting NCT03364218 - Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use Phase 4
Enrolling by invitation NCT03345628 - Feasibility Study for Neurodevelopment Follow-up Study in PICU
Completed NCT04407806 - Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness N/A